ACE inhibitors and AT1 receptor antagonists—beyond the haemodynamic effect

ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect.

and this was associated with increased expression of The classical view of angiotensin II (Ang II ) as a mRNA of extracellular matrix proteins and matrix vasoactive agent that participates in local and systemic deposition. These abnormalities were reduced by ACE haemodynamic regulation has been recently enlarged inhibition and 1 receptor blockade [5,6,12]. to consider it as a true cytokine with...

ACE inhibitors, angiotensin receptor antagonists and bradykinin.

ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells.

OBJECTIVE Human mesothelial cells (HMC) are a major source of intraperitoneal vascular endothelial growth factor (VEGF) and by that are presumably involved in complications of long-term peritoneal dialysis (PD), such as ultrafiltration failure. This prompted us to look for agents that reduce basic mesothelial VEGF production and abrogate VEGF-overproduction induced by proinflammatory cytokines ...

ACE, ACE inhibitors, and other JNK.

The renin-angiotensin system (RAS) plays a pivotal role in the regulation of blood pressure, volume homeostasis, vascular function, and cell growth. In what is considered the classic RAS, renin is released from juxtaglomerular cells of the kidney into the circulation where it converts angiotensinogen from the liver to angiotensin I. Angiotensin I is subsequently hydrolyzed by a peptidyl dipepti...

[New therapeutic targets for ACE inhibitors and angiotensin receptor blockers].

Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) posses multiple beneficial effects such as cardioprotection, cerebroprotection, nephroprotection which provide opportunity to select the most suitable drug for the target vascular bed (e.g. coronary, or cerebral circulation). In some clinical settings, combined therapy ACE-I with ARB (double blockage of the...